POSC52 Cost-Effectiveness of Atezolizumab in Association with Bevacizumab for Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Using a French Real-World Evidence Database

Abstract

In most cost-effectiveness analyses, data are sourced from clinical trials and/or clinical guidelines. The objective of this study was to evaluate the impact on the cost-effectiveness of Tecentriq+Bevacizumab (T+A) in hepatocellular carcinoma (HCC) in a model populated with real-world evidence from the French Système National des Données de Santé (SNDS). Sensitivity analyses using adjusted extrapolations based on the Guyot’s method and macrocosting were considered in this French-based cost-effectiveness analysis.